The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move that strengthens Novartis's position in the advanced therapies market, the company secured European Commission approval for its gene therapy, Itvisma. This drug marks the first gene replacement therapy for Spinal Muscular Atrophy (SMA) to target a broad patient population in Europe. According to reports, the approval covers diverse age groups ranging from newborns to adults, significantly expanding treatment options for this rare genetic disorder.
This regulatory milestone arrives amid intensifying competition in the gene therapy sector, where Novartis competes with major players like Biogen and Roche, which offer Spinraza and Evrysdi respectively. Per market data, Novartis holds a market capitalization of approximately $215 billion (via Yahoo Finance), and Itvisma is viewed as a key growth driver for international sales following similar successes in the U.S. market.
Regarding market performance, NVS stock stood at $154.14 (at close July 1, 2026), after reaching a daily high of $155.02. Investors are now looking toward the upcoming speech by ECB President Christine Lagarde on June 29, 2026, which may impact healthcare sector sentiment in European markets, alongside China's Manufacturing PMI data at month-end to gauge global demand.